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1835between HDL-C and vascular events was not observed
in patients using intensive statin therapy in the primary
prevention setting. Although these results have been
disputed (10,11), statin trials in patients with coronary
artery disease have seen a similar lack of the inverse
relation between HDL-C and risk of vascular events in
patients receiving (intensive) statin therapy (12,13).
Thus far, ﬁndings concerning the absence of increased
risk with low HDL-C levels primarily come from statin
trials, in which patients are treated with a ﬁxed statin
dose. However, this is not a reﬂection of clinical practice
as, according to current guidelines, LDL-C is treated to
target, with various dosages of different statins including
combination therapy. However, as many patients with
clinically manifest vascular disease are treated with sta-
tins, the residual risk from HDL-C in these patients
may be smaller than initially thought. Currently, phar-
macologic methods to increase HDL-C, such as cho-
lesteryl ester transfer protein (CETP) inhibition, are
investigated for their potential ability to further decrease
vascular risk in addition to intensive statin therapy in
patients with vascular disease (14), but the results of
CETP inhibitors in terms of reduction in vascular risk
are as yet disappointing. The CETP inhibitor dalce-
trapib did not show a beneﬁcial effect on endothelial
function (15) or vascular events (16) when added to
statin therapy, despite a 30% increase in HDL-C. Also,
the AIM-HIGH (Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglycer-
ides: Impact on Global Health Outcomes) (17) study, in
which extended release niacin was added to intensive
statin therapy to increase HDL-C, did not show
beneﬁcial results, although the increase in HDL-C was
only modest in this trial. The results of the HPS2
THRIVE (Heart Protection Study 2-Treatment of
HDL to Reduce the Incidence of Vascular Events) trial,
comparing extended release niacin/laropiprant and statin
therapy (including ezetimibe if necessary) with statin
(including ezetimibe if necessary), also showed no
beneﬁcial effects of niacin when added to statin therapy
(18,19).
In the present study, we evaluated the risk associated with
plasma levels of HDL-C in patients with clinical manifes-
tations of vascular disease with or without lipid-lowering
therapy. Furthermore, we evaluated the inﬂuence of the
intensity of treatment on the relation between HDL-C and
vascular events and whether this is inﬂuenced by achieved
levels of LDL-C.Methods
Patients. Data were used from patients enrolled in the
SMART (SecondManifestation of ARTerial disease) cohort.
This is a prospective, ongoing cohort study at the University
Medical Center Utrecht, the Netherlands, designed to study
the presence of concomitant arterial diseases and risk factorsfor atherosclerosis in a high-risk
population. Patients newly refer-
red to our institution with clini-
cally evident vascular disease or
a vascular risk factor (hyperlipid-
emia, hypertension, or diabetes)
were asked to participate. Written
informed consent was obtained
from all patients. The Medical
Ethics Committee of the Univer-
sity Medical Center Utrecht ap-
proved the study.
After inclusion, all patients un-derwent a vascular screening protocol including a health
questionnaire, laboratory measurements, and physical
examination. A detailed description of the study design has
been published previously (20).
For the present study, data were used from 6,123 patients
enrolled in the SMART study between September 1996 and
March 2011 with either a history or a recent diagnosis of
clinically manifest arterial disease: coronary artery disease,
cerebrovascular disease, peripheral artery disease, or aneu-
rysm of the abdominal aorta. Patients could be classiﬁed into
more than 1 disease category. Patients with HDL-C
>3.0 or <0.4 mmol/l were excluded (n ¼ 12) to exclude
patients with monogenetic causes of low or high HDL-C;
hence, the study population consisted of 6,111 patients.
Single imputation methods were used to reduce missing
covariate data for smoking (n ¼ 26; 0.4%), alcohol use
(n ¼ 29; 0.5%), body mass index (BMI) (n ¼ 10; 0.2%),
total cholesterol (n ¼ 1; 0.02%) and plasma triglycerides
(TG) (n ¼ 2; 0.03%), since complete case analysis leads
to loss of statistical power and to bias.
Laboratory assessment. Baseline lipid levels were obtained
from fasting patients. Plasma total cholesterol and TG were
measured using commercial enzymatic dry chemistry kits
(Johnson & Johnson, New Brunswick, New Jersey). HDL-
C in plasma was determined using a commercial enzymatic
kit (Boehringer-Mannheim, Mannheim, Germany) after
precipitation of LDL-C and very low-density lipoprotein
cholesterol with sodium phosphotungstate magnesium
chloride. LDL-C was calculated using the Friedewald
formula up to a plasma TG level of 9 mmol/l, which is in
line with data showing that the Friedewald formula can
be used up to this level (21), to avoid many missing
values in the low HDL-C category. Calculated LDL-C
levels <0.5 mmol/l were regarded as unreliable and not
used for analyses. As a result, LDL-C levels could be
calculated for 6,085 of 6,111 patients (99.6%).
Coding of lipid-lowering medication. Type and dose of
lipid-lowering therapy was registered for all participants. To
compare the intensity of different types of drugs, the theo-
retical percentage of LDL-C reduction per individual type
and dose of lipid-lowering therapy was determined, based on
(systematic) reviews and meta-analyses to the efﬁcacy of
statins and other lipid-lowering drugs (22–24). For the
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1836present study, intensive lipid-lowering medication was
deﬁned as lipid-lowering medication theoretically lowering
LDL-C 40%. This implies that, for example, pravastatin
and ﬂuvastatin will not fall in the intensive lipid-lowering
group at any dose, whereas rosuvastatin will be deﬁned
as intensive lipid-lowering therapy in all doses. For ator-
vastatin and simvastatin, this will depend on the dose used,
with 20 mg atorvastatin and 40 mg simvastatin being
considered intensive lipid-lowering therapy. Furthermore,
we accounted for the addition of other lipid-lowering drugs.
For example, combination therapy with ezetimibe 10 mg
was also regarded as intensive therapy, since this was only
used in combination with simvastatin and atorvastatin.
Besides this, categories of lipid-lowering therapy were
deﬁned according to theoretical LDL-C reduction. This
resulted in 4 categories, with reductions of 1% to <30%
(category 1), 30% to <40% (category 2), 40% to <45%
(category 3), and 45% (category 4). Detailed information
about these categories is shown in Online Table 1.
Follow-up. All study participants received a questionnaire
every 6 months during the follow-up period to obtain
information about hospitalizations and outpatient clinic
visits. All available relevant data from any reported possible
event were collected. Death of a participant was reported by
relatives, the general practitioner, or the specialist who
treated the participant. All events were classiﬁed indepen-
dently by 3 members of the SMART Study Endpoint
Committee, which comprised physicians from different
departments. The outcomes of interest for this study were
a composite of vascular death, myocardial infarction, or
ischemic stroke (a deﬁnition of these outcomes is shown in
Online Table 2). Follow-up duration (years) was deﬁned as
the period between study inclusion and ﬁrst cardiovascular
event or death from any cause, date of loss to follow-up, or
the pre-selected date of March 1, 2011.
Data analysis. Baseline characteristics are presented accord-
ing to quartiles of HDL-C. Male and female patients were
divided separately into HDL-C quartiles and then combined
(sex-pooled quartiles) to prevent over-representation of
females in the highest HDL-C quartiles.
The effect of plasma HDL-C levels on the occurrence of
vascular events was evaluated using Cox proportional hazards
models. Hazard ratios (HRs) and 95% conﬁdence intervals
(CIs) were calculated for HDL-C as a continuous variable
per 0.1 mmol/l increase in HDL-C. The HRs were adjusted
for age and sex in model 1, with additional adjustment
for type 2 diabetes mellitus, BMI, and plasma TG in model
2, all of which may confound the relationship between
plasma HDL-C and vascular events. In model 3, model 2
was additionally adjusted for current smoking and use of
alcohol. In an exploratory analysis, we adjusted for all baseline
factors (model 4: model 3 þ localization of vascular disease,
systolic blood pressure, estimated glomerular ﬁltration rate,
and LDL-C). Analyses were performed using the endpoints
of myocardial infarction, ischemic stroke, vascular death, and
a composite endpoint of all vascular events, which wascomprised of myocardial infarction, stroke, and vascular death.
Patientswere censored if theywere lost to follow-up (3.8%).To
investigate whether the effect of HDL-C on vascular events
was inﬂuenced by the use of (intensive) lipid-lowering medi-
cation, these analyses were stratiﬁed into patients using no
lipid-lowering medication, using nonintensive lipid-lowering
medication, or using intensive lipid-lowering medication.
To identify whether LDL-C level inﬂuenced the effect of
HDL-C on vascular events and whether a potential modi-
ﬁcation by lipid-lowering medication could be explained by
the LDL-C lowering effect, additional analyses were per-
formed with stratiﬁcation for LDL-C level at cutoff values
of 2.0, 2.5, 3.0, and 4.0 mmol/l.
Additionally, the above analyses were visualized by
calculating the HR for increasing quartiles of HDL-C in
strata of lipid-lowering medication or LDL-C level.
Finally, we divided the lipid-lowering therapy into
4 categories based on the amount of LDL-C reduction
to estimate an HR for HDL-C in these categories (cate-
gories: lipid-lowering medication reducing LDL-C <30%,
30% to <40%, 40% to <45%, and 45%).
To test for interaction, that is, whether the relation
between plasma HDL-C levels and vascular events was
modiﬁed by the use of (intensive) lipid-lowering medication
or LDL-C level, we included an interaction term in the Cox
model. If the p value of the interaction term was < 0.05,
effect modiﬁcation was considered to be present. Since
the difference in baseline characteristics between the groups
using no lipid-lowering therapy, usual dose lipid-lowering
therapy, and intensive lipid-lowering therapy could pos-
sibly explain a differential effect of HDL-C in the different
strata, we constructed a propensity score to adjust for these
between-group differences. We constructed a propensity
score for use of lipid-lowering therapy in general and a
propensity score for use of intensive lipid-lowering therapy
using all baseline characteristics (also including use of
antiplatelet agents or blood pressure lowering agents and
time since inclusion) for this propensity score. The Cox
model adjusted for age, sex, type 2 diabetes mellitus, body
mass index, plasma triglycerides, smoking, alcohol usage,
LDL-C level, and the propensity score.
The proportional hazard assumption for the Cox model
was tested using scaled Schoenfeld residuals, conﬁrming
proportional hazards. Only in patients using non-intensive
lipid-lowering medication, the proportional hazard as-
sumption did not hold overall due to non-proportional
hazards for age. In these patients, the HR should be inter-
preted as an average over time.
Analyses were performed using statistical package R 2.13
(R Core Team, Vienna, Austria). For all analyses, p < 0.05
was considered signiﬁcant.Results
Baseline characteristics. With increasing quartiles of
HDL-C, the mean BMI and waist circumference declined
Table 1 Baseline Characteristics According to Sex-Pooled Quartiles of HDL-C
Quartile 1
(n ¼ 1,560)
Quartile 2
(n ¼ 1,514)
Quartile 3
(n ¼ 1,523)
Quartile 4
(n ¼ 1,514) p Value
HDL-C (mmol/l) 0.85  0.12 1.08  0.12 1.28  0.14 1.68  0.31
Male 0.41–0.93 0.94–1.10 1.11–1.32 1.33–2.94
Female 0.50–1.12 1.13–1.36 1.37–1.64 1.65–2.94
Age (yrs) 58.4  10.6 60.1  10.2 60.2  10.4 61.5  10.2 <0.01
Male 1,169 (75) 1,105 (73) 1,134 (75) 1,134 (75) 0.57
BMI (kg/m2) 28.1  4.3 27.1  3.8 26.6  3.8 25.5  3.5 <0.01
Waist circumference* (cm) 99.3  11.9 96.4  11.6 95.1  11.2 92.0  11.6 <0.01
Metabolic syndrome 1,353 (87) 999 (66) 564 (37) 345 (23) <0.01
Type 2 diabetes mellitus 370 (24) 287 (19) 216 (14) 149 (10) <0.01
Systolic blood pressure (mm Hg) 139  21 141  21 141  21 144  21 <0.01
Diastolic blood pressure (mm Hg) 81  11 81  11 81  11 83  11 <0.01
Total cholesterol (mmol/l) 4.8  1.3 4.9  1.2 4.9  1.1 5.1  1.1 <0.01
LDL-C (mmol/l) 3.0  1.1 3.0  1.1 2.9  1.0 2.8  1.0 <0.01
Triglycerides (mmol/l) 2.3  1.4 1.7  1.1 1.6  1.3 1.2  0.7 <0.01
eGFR (ml/min/1.73 m2)y 75  19 75  18 76  17 77  18 0.04
Alcohol use during last year 953 (61) 1,000 (66) 1,114 (73) 1,250 (83) <0.01
Current smoking 628 (40) 512 (34) 453 (30) 425 (28) <0.01
Lipid-lowering medication 956 (61) 997 (66) 1,026 (67) 979 (65) <0.01
Intensive lipid-lowering medicationz 484 (31) 520 (34) 544 (36) 498 (33) 0.04
Localization of vascular disease
Coronary artery disease 961 (62) 979 (65) 928 (61) 819 (54) <0.01
Cerebrovascular disease 427 (27) 368 (24) 453 (30) 503 (33) <0.01
Peripheral arterial disease 362 (23) 311 (21) 262 (17) 298 (20) <0.01
Abdominal aortic aneurysm 157 (10) 138 (9) 123 (8) 124 (8) 0.18
Values are mean  SD, range, or n (%). *Available for patients included from 1999 onwards. yGlomerular ﬁltration rate, as estimated by the Modiﬁcation of Diet in Renal Disease (MDRD) equation.
zDeﬁned as lipid-lowering medication lowering LDL-C with 40%.
BMI ¼ body mass index; eGFR ¼ estimated glomerular ﬁltration rate; HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-cholesterol.
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2 diabetes mellitus was lower (Table 1). The proportion of
patients using lipid-lowering medication was approximately
65%, and this did not differ across HDL-C quartiles.
Almost two-thirds of patients had coronary artery disease,
although the frequency was slightly lower in the highest
quartile of HDL-C. About one-third of the patients had
cerebrovascular disease.
Plasma HDL-C and the risk of recurrent vascular events
according to use of lipid-lowering medication. Median
follow-up was 5.4 years (interquartile range: 2.9 to 8.6
years). During this follow-up, 874 new vascular events
occurred (myocardial infarction, stroke, and vascular death).
Per 0.1 mmol/l increase in HDL-C, the risk of vascular
events decreased 5% (HR: 0.95; 95% CI: 0.92 to 0.99) in
patients not using lipid-lowering medication (Table 2).
Additional adjustment for baseline factors in model 4 did
not affect this relation. Similar relations were seen between
HDL-C and myocardial infarction (HR: 0.93; 95% CI:
0.88 to 0.97), ischemic stroke (HR: 0.95; 95% CI: 0.89 to
1.01), and vascular death (HR: 0.97; 95% CI: 0.93
to 1.01).
In patients on usual dose lipid-lowering therapy (n ¼
1,910), the risk for all vascular events per 0.1 mmol/l
increase in HDL-C decreased 6% (HR: 0.94; 95% CI:
0.90 to 0.98) (Table 2). However, in patients usingintensive lipid-lowering medication, HDL-C plasma
levels were not associated with vascular events (HR:
1.02; 95% CI: 0.98 to 1.07). Furthermore, HDL-C was
not associated with myocardial infarction (HR: 0.99;
95% CI: 0.93 to 1.07), ischemic stroke (HR: 1.01; 95%
CI: 0.93 to 1.10), or vascular death (HR: 1.07; 95% CI:
1.00 to 1.16). The p for interaction in model 3, after
additional adjustment for a possible differential effect of
LDL-C level and propensity score, was 0.03, indicating
modiﬁcation of the effect of HDL-C by intensive lipid-
lowering treatment, irrespective of LDL-C or baseline
differences between the groups. In quartiles of higher
HDL-C, the risk of vascular events was lower in
patients on usual dose lipid-lowering therapy compared
with the lowest HDL-C quartile (Fig. 1A). For patients
on intensive lipid-lowering therapy, the overall risk
for vascular events is lower compared with patients
using no or usual dose lipid-lowering, but there was no
relation between HDL-C and vascular risk in that group
(Fig. 1B). An association between HDL-C and vascular
events in patients on intensive lipid-lowering therapy was
absent independent of the year of inclusion and was
absent both in patients with low levels of CRP (<2 mg/l)
or high levels of CRP (2 mg/l). Analyses only based on
statin treatment instead of lipid-lowering therapy in
general did not change the results.
Table 2 Risk of Vascular Events by HDL-C According to Lipid-Lowering Treatment
No Lipid-Lowering
(n ¼ 2,153)
Usual Dose Lipid-Lowering
(n ¼ 1,910)
Intensive Lipid-Lowering
(n ¼ 2,046)
All vascular events 454 262 158
Model 1 0.95 (0.92–0.97) 0.93 (0.89–0.97) 0.99 (0.95–1.04)
Model 2 0.95 (0.92–0.98) 0.93 (0.89–0.97) 1.00 (0.96–1.05)
Model 3 0.95 (0.92–0.99) 0.94 (0.90–0.98) 1.02 (0.98–1.07)
Model 4 0.96 (0.93–1.00) 0.94 (0.90–0.98) 1.03 (0.98–1.08)
Myocardial infarction 222 157 79
Model 1 0.92 (0.88–0.96) 0.90 (0.85–0.95) 0.98 (0.91–1.04)
Model 2 0.93 (0.88–0.97) 0.90 (0.85–0.96) 0.98 (0.91–1.05)
Model 3 0.93 (0.88–0.97) 0.91 (0.85–0.97) 0.99 (0.93–1.07)
Model 4 0.93 (0.89–0.98) 0.91 (0.86–0.97) 1.00 (0.93–1.08)
Ischemic stroke 108 61 49
Model 1 0.96 (0.90–1.01) 0.95 (0.87–1.03) 0.98 (0.90–1.06)
Model 2 0.95 (0.89–1.02) 0.96 (0.88–1.05) 0.99 (0.91–1.07)
Model 3 0.95 (0.89–1.01) 0.97 (0.88–1.06) 1.01 (0.93–1.10)
Model 4 0.96 (0.90–1.03) 0.96 (0.88–1.06) 1.00 (0.91–1.09)
Vascular death 312 131 69
Model 1 0.95 (0.92–0.99) 0.90 (0.85–0.96) 1.04 (0.98–1.11)
Model 2 0.97 (0.93–1.01) 0.91 (0.85–0.97) 1.05 (0.98–1.13)
Model 3 0.97 (0.93–1.01) 0.91 (0.85–0.98) 1.07 (1.00–1.15)
Model 4 0.98 (0.94–1.02) 0.92 (0.86–0.98) 1.09 (1.01–1.17)
Values are number of events or hazard ratio (95% conﬁdence interval) per 0.1 mmol/l increase in HDL-C, stratiﬁed for no lipid-lowering therapy, usual dose
(e.g., pravastatin, atorvastatin 10 mg), or intensive lipid-lowering therapy (e.g., atorvastatin 20 to 80 mg, rosuvastatin). Model 1: Adjusted for age and sex.
Model 2: Model 1 þ type 2 diabetes mellitus, body mass index, and plasma triglyceride levels. Model 3: Model 2 þ smoking and alcohol. Model 4: Model
3 þ localization of vascular disease, systolic blood pressure, eGFR, and LDL-C.
Abbreviations as in Table 1.
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according to LDL-C level. The relation between HDL-C
and risk for vascular events was not modiﬁed by LDL-C
(p for interaction ¼ 0.3). Table 3 shows the HR per 0.1
mmol/l increase in HDL-C at different LDL-C levels,
stratiﬁed for use of lipid-lowering medication. In patients
using lipid-lowering medication, HDL-C was not related
to risk of vascular events at LDL-C levels <2.0 mmol/l.
Of these patients, 70% used intensive lipid-lowering medi-
cation. In patients with LDL-C 2.0 mmol/l, increasing
HDL-C levels were related to a lower vascular risk. Adjust-
ment for all baseline factors did not change the results (data
not shown), although the number of events may not be
sufﬁcient in all strata to allow ﬁrm conclusions.
Plasma HDL-C and the risk of recurrent vascular events
according to intensity of lipid-lowering therapy. The
intensity of lipid-lowering therapy modiﬁed the relation
between HDL-C and vascular events (Table 4). In patients
using lipid-lowering therapy that lowers LDL-C <30%, the
risk for vascular events was 5% lower (HR: 0.95; 95% CI:
0.88 to 1.02) for each 0.1 mmol/l increase in HDL-C. The
inverse association between HDL-C and vascular events
gradually changed with increasing intensity of lipid-lowering
medication. In patients on lipid-lowering therapy that is
considered to lower LDL-C >45%, there was no relation
between HDL-C and vascular events (HR: 1.06; 95%
CI: 0.99 to 1.15). The p for interaction by intensity of lipid-
lowering therapy was 0.03. Adjustment for all baseline
factors did not change the results (data not shown).Discussion
In patients with clinically manifest vascular disease not
treated with lipid-lowering medication or treated with
usual dose lipid-lowering medication, low HDL-C was
associated with an increased risk of recurrent vascular events;
in contrast, in patients on intensive dose lipid-lowering
therapy, HDL-C was not associated with vascular events.
The plasma level of LDL-C did not modify the effect of
HDL-C on vascular events.
Low plasma HDL-C is recognized as a risk factor for
(recurrent) vascular events (1–4), and our results conﬁrm
these ﬁndings for patients using no or usual dose lipid-
lowering therapy. However, several trials such as JUPITER
(9), CARE (Cholesterol and Recurrent Events) (12), and
PROVE IT–TIMI 22 (Pravastatin or Atorvastatin Evalua-
tion and Infection Therapy–Thrombolysis In Myocardial
Infarction 22) (13), report absence of an association between
low HDL-C and vascular events in patients with and with-
out vascular disease on statin therapy. An important differ-
ence between these trials and clinical practice is the ﬁxed
statin dose used in trials instead of treating to a target, as
is advocated in European and American treatment guide-
lines (25,26). In a recent report from the Crusade registry,
HDL-C was also not associated with recurrent myocardial
infarction or death in patients with myocardial infarction on
statin therapy, but type and dose of statin therapy was not
speciﬁed (27). Our study is a real-life situation in which
patients are treated to an LDL-C target, as advocated in
Figure 1 Risk for All Vascular Events Across Quartiles of HDL-C
(A) Hazard ratio (HR) (95% conﬁdence interval) by increasing quartiles of high-
density lipoprotein cholesterol (HDL-C), stratiﬁed for yes versus no lipid-lowering
therapy, adjusted for age, sex, body mass index, type 2 diabetes mellitus, plasma
triglyceride level, alcohol use, and smoking. (B) HR (95% conﬁdence interval) by
increasing quartiles of HDL-C, stratiﬁed for yes versus no intensive lipid-lowering
therapy (deﬁned as 40% low-density lipoprotein cholesterol reduction), adjusted
for age, sex, body mass index, type 2 diabetes mellitus, plasma triglyceride level,
alcohol use, and smoking. The reference group includes both patients using no
lipid-lowering medication and patients using usual dose lipid-lowering medication.
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1839clinical guidelines, with information about different doses
and types of lipid-lowering medication that were used, in
contrast to a single ﬁxed dose in clinical trials. We are able to
evaluate a wide range of different lipid-lowering medication,
instead of comparing 2 different doses or comparing a single
dose with placebo. Therefore, we could demonstrate a gradualTable 3 Risk of Vascular Events by HDL-C According to LDL-C Level
LDL-C (mmol/l) <2.0 2.0 to <2.5
Lipid-lowering therapy 1,027 (79) 997 (84)
Model 1 1.01 (0.95–1.07) 0.96 (0.90–1.03)
Model 2 1.00 (0.94–1.07) 0.97 (0.90–1.04)
Model 3 1.02 (0.95–1.09) 0.97 (0.90–1.05)
No lipid-lowering therapy 297 (43)
Model 1 0.95 (0.87–1.03)
Model 2 0.94 (0.85–1.03)
Model 3 0.94 (0.86–1.04)
Values are n (events) or hazard ratio (95% conﬁdence interval) per 0.1 mmol/l increase in HDL-C, strati
therapy, few patients (n ¼ 124) had LDL-C levels <2.0 mmol/l; therefore, these patients were added to
Model 1 þ type 2 diabetes mellitus, body mass index, and plasma triglyceride levels. Model 3: Model 2
Abbreviations as in Table 1.decrease of the inverse association between HDL-C and
outcomes with increasing intensity of lipid-lowering treat-
ment. This observation is consistent with a report from the
TNT (Treating to New Targets) trial (28), in which HDL-C
was associated with vascular events in the atorvastatin 10 mg
group, whereas it was not associated with vascular events in
the atorvastatin 80mg group. Our results obtained in a cohort
study indicate that not merely statin treatment, but also
treatment intensity affects the relation between HDL-C
plasma concentrations and vascular risk. In contrast to our
ﬁndings, other cohort studies in patients with vascular disease
treated with statins according to current guidelines have re-
ported that HDL-C was still inversely associated with
vascular events (8,29). However, intensity of lipid-lowering
therapy was not reported, and the average LDL-C reduc-
tion of 28% (8) and/or the reached LDL-C level of approx-
imately 130 mg/dl (3.4 mmol/l) (29) suggests that not all
patients were on intensive statin therapy. In the present real-
life study, all lipid-lowering therapy, mainly statins and
cholesterol absorption inhibitors, were taken into account to
estimate an expected proportion of LDL-C reduction as
a measure of intensity of lipid-lowering treatment. Previous
reports about lipid-lowering treatment modifying the relation
between HDL-C and vascular events speciﬁcally only
considered statin therapy. The lipid-lowering treatment used
in the present study was also primarily statin therapy, and,
therefore, these results can be compared with previous reports
in statin-treated patients. In a sensitivity analysis, performing
analyses only based on statin treatment did not change the
results.
In concordance with our results, studies in patients with
and without vascular disease have shown that low HDL-C
levels are related to increased vascular risk irrespective of
plasma LDL-C level (4,7), even at LDL-C <1.8 mmol/l
(28,30). The present study conﬁrms these ﬁndings, although
few patients reached very low LDL-C levels without
receiving intensive statin therapy. The association between
HDL-C and vascular events was not modiﬁed by LDL-C
level. The inverse association between HDL-C and
vascular events was not present only in patients with LDL-C
<2 mmol/l on lipid-lowering therapy, and this is consistent2.5 to <3.0 3.0 to <4.0 4.0
861 (88) 803 (123) 250 (42)
0.97 (0.91–1.04) 0.90 (0.84–0.96) 0.93 (0.84–1.04)
0.98 (0.91–1.06) 0.91 (0.84–0.98) 0.94 (0.85–1.06)
1.01 (0.94–1.09) 0.92 (0.86–0.99) 0.96 (0.86–1.07)
301 (46) 812 (180) 737 (183)
0.97 (0.90–1.05) 0.95 (0.90–1.00) 0.94 (0.89–0.99)
0.97 (0.90–1.06) 0.97 (0.91–1.02) 0.93 (0.88–0.99)
0.98 (0.90–1.07) 0.97 (0.92–1.02) 0.94 (0.89–1.00)
ﬁed for LDL-C level separately for use of lipid-lowering therapy. For patients using no lipid-lowering
the patients with LDL-C levels of 2.0 to <2.5 mmol/l. Model 1: Adjusted for age and sex. Model 2:
þ smoking and alcohol.
Table 4 Risk of Vascular Events by HDL-C in Categories of Increasingly Potent Lipid-Lowering Therapy
Category of Lipid-Lowering Therapy n (Events) LDL-C Level (mmol/l)
Risk for Vascular Events Per 0.1 mmol/l Increase
Model 1 Model 2 Model 3
1 (1% to <30%) 763 (114) 2.9  0.8 0.92 (0.86–0.98) 0.93 (0.87–1.00) 0.95 (0.88–1.02)
2 (30% to <40%) 1,144 (148) 2.7  0.8 0.93 (0.88–0.99) 0.93 (0.88–0.99) 0.94 (0.88–1.00)
3 (40% to <45%) 1,310 (92) 2.4  0.8 0.98 (0.92–1.04) 0.99 (0.93–1.05) 1.01 (0.95–1.07)
4 (45%) 735 (65) 2.3  0.9 1.02 (0.95–1.10) 1.04 (0.97–1.13) 1.06 (0.99–1.15)
p value for interaction lipid-lowering therapy  HDL-C 0.03 0.03 0.03
Categories of lipid-lowering therapy were deﬁned according to theoretical LDL-C reduction: 1% to <30%, 30% to <40%, 40% to <45%, and <45%. Model 1: adjusted for age and sex. Model 2: Model 1 þ
type 2 diabetes mellitus, body mass index, and plasma triglyceride levels. Model 3: Model 2 þ smoking and alcohol.
Abbreviations as in Table 1.
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1840with the high prevalence of intensive lipid-lowering treat-
ment in this group.
Although all patients in our study would qualify for
treatment with lipid-lowering treatment, a part of these
patients was not treated at baseline. These patients were
generally included earlier in this study, which started in
1996, when the use of lipid-lowering therapy was lower. In
addition, in patients with cerebrovascular disease, peripheral
arterial disease, or an abdominal aortic aneurysm, the use of
lipid-lowering therapy was generally lower at baseline
compared with patients with coronary artery disease.
However, the propensity score also included year of inclu-
sion and localization of disease, and the p for interaction was
still statistically signiﬁcant after adjustment for a differential
effect of these factors and the other baseline variables
included in the propensity score.
Our results do not allow conclusions about the possible
effect of HDL-C raising therapy in a population of patients
with vascular disease. Randomized controlled trials are
necessary to evaluate the effect of HDL-C raising therapy
in these patients. Although a Mendelian randomization
study indicated that HDL-C as such may not be a causal
factor in vascular disease (31), and previous trials with
CETP inhibitors (16,32) or niacin (17–19) to increase
HDL-C in addition to intensive statin treatment showed
no reduction of cardiovascular events, the new CETP
inhibitors anacetrapib and evacetrapib also reduce LDL-C
and may, therefore, lower cardiovascular risk due to LDL-C
reduction. In addition, interventions targeted at increasing
HDL-C that also affect HDL function could still be
beneﬁcial in patients with vascular disease. However, the
results of the present study indicate that in patients using
intensive statin therapy, HDL-C may not be a good
secondary treatment target, and these results could provide
an alternative explanation for the failure of CETP inhibi-
tors to show any beneﬁt in addition to intensive statin
treatment. Explanations for the apparent absence of a rela-
tion between HDL-C and vascular events in patients
treated with intensive lipid-lowering therapy can only be
speculated upon. Although statins marginally increase
HDL-C depending on type and dose and beneﬁcially
inﬂuence several molecules in HDL metabolism such as
CETP, lipoprotein lipase, and paraoxonase-1 (33), theconsequences of these effects on HDL function remain
poorly understood. Whether the results of the present study
can be explained by functional changes in HDL during
intensive statin therapy, whether the relation between HDL
function and plasma HDL-C level is lost in intensive statin
therapy, or whether anti-inﬂammatory and antioxidant
properties of HDL-C are less relevant as high-dose statin
therapy already exerts anti-inﬂammatory and antioxidant
actions is not known.
Study limitations. Plasma lipid levels were measured only
once at the start of the study. Moreover, only data about
baseline medication was available, which is likely to have
changed during follow-up. It is likely that the number of
patients receiving lipid-lowering therapy and the proportion
of patients receiving intensive lipid-lowering treatment during
follow-up has increased. Most patients receiving intensive
statin therapy already at baseline are likely to continue use of
intensive therapy during follow-up. Therefore, a “drop-in” of
lipid-lowering therapy in the patients not using lipid-lowering
therapy at baseline would likely only decrease the difference
between the groups and, hence, lead to an underestimation of
the difference in effect of HDL-C in patients using or not
using intensive lipid-lowering therapy. Second, stratiﬁcation
of our study population in different LDL-C categories
resulted in a small number of events in some groups, atten-
uating the precision of the risk estimation. Drawing ﬁrm
conclusions from the results in different LDL-C categories
should therefore be done with caution, but these analyses
serve to give an overall impression of the effect of HDL-C at
increasing levels of LDL-C.
Conclusions
HDL-C levels are related to the risk of new cardiovascular
events in patients with clinically manifest vascular disease
treated with usual dose lipid-lowering therapy but not in
patients treated with intensive lipid-lowering medication,
irrespective of LDL-C.
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